Nilotinib: A phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases

Future Oncology

Volumn 4, Issue 5, 2008, Pages 611-621

  Quintás Cardama, Alfonso ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BOSUTINIB; DASATINIB; EVEROLIMUS; IMATINIB; INTERFERON; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NILOTINIB; OXIDOREDUCTASE; OXIDOREDUCTASE NQO2; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE KIT; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TYROSINE KINASE RECEPTOR; TYROSINE KINASE RECEPTOR DDR1; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; AUTOPHOSPHORYLATION; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; ENZYME ACTIVITY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC TRANSFORMATION; HUMAN; HYPERBILIRUBINEMIA; HYPEREOSINOPHILIA; HYPEREOSINOPHILIC SYNDROME; MONOTHERAPY; NEUTROPENIA; NEUTROPENIC SEPSIS; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PLASMA CONCENTRATION-TIME CURVE; PLEURA EFFUSION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SIDE EFFECT; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; STEM CELL FACTOR;

EID: 55249102194     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.5.611     Document Type: Review

References (55)

1. Nowell P, Hungerford D: A minute chromosome in human chronic granulocytic Leukemia Science 132, 1497 (1960).
2. Rowley JD: Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290-293 (1973).
3. Druker BJ, Guilhot F, O'Brien SG et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid Leukemia N. Engl. J. Med. 355, 2408-2417 (2006).
4. Kantarjian HM, Cortes JE, O'Brien S et al.: Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α. Blood 104, 1979-1988 (2004).
5. Hughes TP, Kaeda J, Branford S et al.: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423-1432 (2003).
6. Cortes J, Talpaz M, O'Brien S et al.: Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin. Cancer Res. 11, 3425-3432 (2005).
7. Druker BJ, Sawyers CL, Kantarjian H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001).
8. Hochhaus A, La Rosee P: Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18, 1321-1331 (2004).
9. Shah NP, Nicoll JM, Nagar B et al.: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (ST1571) in chronic phase and blast crisis chronic myeloid leukaemia. Cancer Cell 2, 117-125 (2002).
10. Gorre ME, Mohammed M, Ellwood K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001).
11. Lowenberg B: Minimal residual disease in chronic myeloid leukemia. N. Engl. J. Med. 349, 1399-1401 (2003).
12. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101, 4611-4614 (2003).
13. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L: Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 4, 75-85 (2003).
14. O'Hare T, Walters DK, Stoffiregen EP et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65, 4500-4505 (2005).
15. Deininger M, Buchdunger E, Druker BJ: The development of imatinib as a therapeutic agent for chronic myeloid Leukemia Blood 105, 2640-2653 (2005).
16. Carter TA, Wodicka LM, Shah NP et al.: Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl Acad. Sci. USA 102, 11011-11016 (2005).
17. Schindler T, Bornmann W Pellicena P, Miller WT, Clarkson B, Kuriyan J: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942 (2000).
18. Nagar B, Bornmann WG, Pellicena P et al.: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236-4243 (2002).
19. Hantschel O, Nagar B, Guettler S et al.: A myristoyl/ phosphotyrosine switch regulates c-Abl. Cell 112, 845-857 (2003).
20. Azam M, Latek RR, Daley GQ: Mechanisms of autoinhibition and STI-571/ imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112, 831-843 (2003).
21. Skaggs BJ, Gorre ME, Ryvkin A et al.: Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc. Natl Acad. Sci. USA 103, 19466-19471 (2006).
22. Donato NJ, Wu JY, Stapley J et al.: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to ST1571. Blood 101, 690-698 (2003).
23. White DL, Saunders VA, Dang P et al.: OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108, 697-704 (2006).
24. Weisberg E, Manley PW, Breitenstein W et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-141 (2005).
25. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br. J. Cancer 94, 1765-1769 (2006).
26. Liu Y, Gray NS: Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358-364 (2006).
27. Hubbard SR, Wei L, Ellis L, Hendrickson VA: Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372, 746-754 (1994).
28. Golemovic M, Verstovsek S, Giles F et al.: AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid Leukemia Clin. Cancer Res. 11, 4941-4947 (2005).
29. Rix U, Hantschel O, Durnberger G et al.: Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110, 4055-4063 (2007).
30. Bradeen HA, Eide CA, O'Hare T et al.: Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108, 2332-2338 (2006).
31. von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J: Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 108, 1328-1333 (2006).
32. Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD: Identification of Bcr/Abl point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 109(11), 5011-5015 (2007).
33. + leukemias. Blood 109, 2112-2120 (2007).
34. White DL, Saunders VA, Quinn SR, Manley PW, Hughes TP: Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs. Blood 109, 3609-3610 (2007).
35. Hirota S, Isozaki K, Moriyama Y et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580 (1998).
36. Heinrich MC, Corless CL, Duensing A et al.: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299, 708-710 (2003).
37. Cools J, DeAngelo DJ, Gotlib J et al.: A tyrosine kinase created by fusion of the PDGFPA and KIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201-1214 (2003).
38. Verstovsek S, Akin C, Manshouri T et al.: Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk. Res. 30, 1365-1370 (2006).
39. Guo T, Agaram NP, Wong GC et al.: Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin. Cancer Res. 13, 4874-4881 (2007).
40. Quintas-Cardama A, Kantarjian H, Cortes J: Flying under the radar: the new wave of BCR-ABL inhibitors. Nat. Rev. Drug Discov. 6, 834-848 (2007).
41. Verstovsek S, Giles FJ, Quintas-Cardama A et al.: Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIPIL1-PDGFR-α-expressing cells. Leuk. Res. 30, 1499-1505 (2006).
42. Stover EH, Chen J, Lee BH et al.: The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRP and FIP1L1-PDGFRα in vitro and in vivo. Blood 106, 3206-3213 (2005).
43. Kantarjian H, Giles F, Wunderle L et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542-2551 (2006).
44. Graham SM, Jorgensen HG, Allan E et al.: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic mycloid leukemia are insensitive to ST1571 in vitro. Blood 99, 319-325 (2002).
45. Jorgensen HG, Copland M, Allan EK et al.: Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocytecolony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin. Cancer Res. 12, 626-633 (2006).
46. Jorgensen HG, Allan EK, Graham SM et al.: Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 19, 1184-1191 (2005).
47. + CML cells. Blood 109(9), 4016-4019 (2007).
48. Kantarjian HM, Giles F, Gattermann N et al.: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110, 3540-3546 (2007).
49. Jabbour E, le Coutre P, Baccarani M et al.: Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP). Proc. Am. Soc. Clin. Oncol. 25, abstract 7039 (2007).
50. le Coutre P, Ottmann OG, Giles F et al.: Nilotinib (formerly AMN 107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous Leukemia Blood 111, 1834-1839 (2008).
51. +) chronic myelogenous leukemia in blast crisis (CML-BC) who are risistant or intolerant to imatinib. Blood 110, abstract 1025 (2007).
52. Giles F, le Coutre P, Bhalla KN et al.: Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC). Blood 110, abstract 1029 (2007).
53. Cortes J, O'Brien S, Jabbour E et al.: Efficacy of nilotinib (AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood 110, abstract 29 (2007).
54. Von Mehren M, Reichardt P, Casali PG et al.: A Phase I study of nilotinib alone and in combination with imatinib (IM) in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) - study update. Proc. Am. Soc. Clin. Oncol. 25, abstract 10023 (2007).
55. le Coutre P, Hochhaus A, Heim D et al.: A Phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with hypereosinophilic syndrome (HES). Blood 108, abstract 4912 (2006).